The coronavirus has begun to affect day-to-day operations at pharma companies, with Biogen dealing with an outbreak linked to a management meeting at an affected hotel, and others telling s
Gilead has said it has begun two phase 3 trials of its potential COVID-19 coronavirus antiviral remdesivir in adults affected by the disease, expanding ongoing research in the US and China.
Gilead’s share price has surged after health experts said its antiviral drug remdesivir is showing signs of efficacy against the deadly COVID-19 coronavirus outbreak.